GuiZhou SanLi Pharmaceutical Co.,Ltd

Shanghai Stock Exchange 603439.SS

GuiZhou SanLi Pharmaceutical Co.,Ltd Price to Earnings Ratio (P/E) on January 27, 2025: 17.57

GuiZhou SanLi Pharmaceutical Co.,Ltd Price to Earnings Ratio (P/E) is 17.57 on January 27, 2025, a -24.26% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

GuiZhou SanLi Pharmaceutical Co.,Ltd 52-week high Price to Earnings Ratio (P/E) is 24.50 on March 18, 2024, which is 39.44% above the current Price to Earnings Ratio (P/E).
GuiZhou SanLi Pharmaceutical Co.,Ltd 52-week low Price to Earnings Ratio (P/E) is 15.16 on August 23, 2024, which is -13.71% below the current Price to Earnings Ratio (P/E).
GuiZhou SanLi Pharmaceutical Co.,Ltd average Price to Earnings Ratio (P/E) for the last 52 weeks is 19.25.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Shanghai Stock Exchange: 603439.SS

GuiZhou SanLi Pharmaceutical Co.,Ltd

CEO	Mr. Hai Zhang
IPO Date	April 28, 2020
Location	China
Headquarters	Xiayun Industrial Park
Employees	2,282
Sector	Health Care
Industries Pharmaceuticals

Description

GuiZhou SanLi Pharmaceutical Co.,LTD. engages in the research and development, production, and marketing of pharmaceutical products. It offers pediatric medication, respiratory system medication, cardiovascular and cerebrovascular drugs, digestive medicine, trauma injury medication, rehabilitation medicine, and ophthalmic medicine. The company was founded in 1995 and is based in Guiyang, China.

Key trends

Past 5 years